^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD39 inhibitor

    Related drugs:
    3ms
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting | N=87 --> 40
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    3ms
    IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors. (PubMed, Cancer Res Commun)
    IPH5201 as monotherapy, or in combination with durvalumab, was well tolerated at pharmacologically active doses that induced reduction of intratumoral CD39 enzymatic activity and showed preliminary evidence for disease stabilization.
    Journal
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Imfinzi (durvalumab) • IPH5201
    3ms
    Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP. (PubMed, J Immunol)
    Using the coculture system, we generated the first transcriptional eATP signature developed on primary human myeloid cells and applied it to real-world datasets, illustrating a response to eATP that can be measured in human tumors. These studies provide a mechanistic rationale for CD39 inhibition to promote antitumor immunity via the enhancement of eATP-driven myeloid cell activation of T cells across a variety of tumor settings and eATP-generative modalities.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • GZMB (Granzyme B) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    4ms
    A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Trial completion date: Sep 2025 --> Feb 2027 | Trial primary completion date: Jun 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    4ms
    ES014-IIT-01: A Study of ES014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=15, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Nov 2024
    Enrollment open • Trial initiation date
    6ms
    A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=8, Completed, Elpiscience Biopharma, Ltd. | Active, not recruiting --> Completed | N=60 --> 8
    Trial completion • Enrollment change
    7ms
    Ultrasound-responsive release of CD39 inhibitor overcomes adenosine-mediated immunosuppression in triple-negative breast cancer. (PubMed, J Control Release)
    Moreover, BFPL effectively triggers a potent antitumor immune response and enhances the efficacy of anti-PD-L1 immunotherapy. Thus, by modulating metabolic pathways to counteract ADO-associated barriers in ICD therapy, this innovative approach holds potential for improving immunotherapy outcomes in TNBC.
    Journal
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    1year
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=87, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Aug 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    1year
    TTX-030-003: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, Trishula Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • eltivutabart (TTX-030)
    1year
    CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway. (PubMed, Int Immunopharmacol)
    These results suggested that POM-1 had synergistic effect with radiotherapy by enhancing cell apoptosis through Bax/Bcl-2 signal pathway in ESCC. The combination of POM-1 and radiotherapy is expected to enhance the anti-tumor effect in ESCC.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    ENTPD1 expression
    over1year
    A Study of ES014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial • Metastases